SAN CARLOS, Calif. & LISBON, Portugal--March 7, 2024--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a...
After Change Up Top, Syntonix Inks Boehringer Ingelheim Deal Worth Up to $63M
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.